Papers from every journal, all in one place. Launch research agents to watch your topics.
Reposted by Bruno Ramos Nascimento
Bruno Ramos Nascimento
Excited to share that our PROVAR+ study on artificial intelligence-enabled electrocardiography for structural heart disease detection and echocardiography prioritization has been selected for presentation as Late-Breaking Science at the American Heart Association Scientific Sessions 2026 in Chicago!
This collaborative research explores how AI can be integrated into established telecardiology networks to improve cardiovascular screening and access to diagnostic imaging in undersourced settings.
Sex-specific impact of left atrial remodelling on heart failure with preserved ejection fraction: a study in arterial hypertensive patients with and without left ventricular hypertrophy
European Heart Journal · Kassab et al. ·
AHA Scientific Sessions 2026 · PROVAR+
Written before results
Bruno Ramos Nascimento
Interventional / Structural Cardiology · Universidade Federal de Minas Gerais
Excited to share that our PROVAR+ study on artificial intelligence-enabled electrocardiography for structural heart disease detection and echocardiography prioritization has been selected for presentation as Late-Breaking Science at the American Heart Association Scientific Sessions 2026 in Chicago!
This collaborative research explores how AI can be integrated into established telecardiology networks to improve cardiovascular screening and access to diagnostic imaging in undersourced settings.
Sex-specific impact of left atrial remodelling on heart failure with preserved ejection fraction: a study in arterial hypertensive patients with and without left ventricular hypertrophy
European Heart Journal · V Pires Kassab et al. ·
Reposted by Raul D. Santos
Raul D. Santos
We'll have important results to discuss soon!
AG
Amit X. Garg
Professor of medicine and epidemiology, Western University · Western University / London Health Sciences Centre
“
We ended up comparing 385 donor pregnancies and 1,540 matched healthy non-donor pregnancies. We did notice a higher risk of gestational hypertension or preeclampsia in the donors compared to the non-donors: rounded off, around 12% in the donors compared to 8% in the non-donors. But overall, many of the pregnancies in donors were healthy, with no difficulty for the mother or child.
Pregnancy Outcomes After Living Kidney Donation
JAMA · Wang et al. ·
AHA Scientific Sessions 2026 · Lp(a)HORIZON
Written before results
Raul D. Santos
General / Preventive / Lipids
Horizon results are highly anticipated, and although it is a neutral trial, it does not diminish the value of measuring Lp(a) for risk stratification.
Pregnancy Outcomes After Living Kidney Donation
JAMA · Carol Wang et al. ·
Reposted by Ofir Koren
Ofir Koren
AVC is a pathological finding, regardless of its burden, and deserves greater recognition. AI offers an opportunity to improve detection and reporting. Building on the MESA findings, we should focus on earlier identification and explore ways to slow disease progression. Most importantly, it is time to bring experts together to develop clear follow-up recommendations, transforming incidental AVC into an opportunity for early intervention and, ultimately, prevention of aortic stenosis.
Dr. Ofir Koren
Cardiology · Cedars-Sinai Medical Center
“
The low reporting rate may reflect the fact that most CT scans were performed for unrelated indications, alongside challenges in assessing aortic valve calcification and the lack of clearly defined clinical pathways for incidental findings. AI-based clinical decision support could help address these challenges by providing consistent detection and quantitative assessment, potentially improving the recognition and reporting of AVC in routine practice.
Artificial Intelligence Detection of Aortic Valve Calcification on Routine Noncontrast Chest CT
JACC Advances · Koren et al. ·
Reposted by Miguel Franquiz
Miguel Franquiz
This is really interesting and would be great to see a full paper/more details. The composite endpoint is very clinically significant (death, VT, ICD shock, transplant), with 4-fold unadjusted HR if follow up PET after diagnosis graded as "unchanged/worsened". Would definitely need more details about IS in the group that was "unchanged/worsened".
Dynamic changes on serial PET predict short- and long-term outcomes in cardiac sarcoidosis
European Heart Journal · Bollano et al. ·
Reposted by Miguel Franquiz
Miguel Franquiz
While very interesting that 91% had positive CVB serologies, prevalence is probably not the best term to use, as to be included in the analysis, patients had to have sarcoidosis and available CVB testing. Prevalence could be defined if all sarcoidosis patients had CVB testing.
High prevalence of coxsackievirus B antibodies in patients with cardiac sarcoidosis: a retrospective cohort study
Open Heart · Donnelly et al. ·
Dr. Viktor Kočka
Interventional Cardiologist · Charles University and University Hospital Kralovske Vinohrady
“
Using the blueprint already employed for heart attacks, we were able to demonstrate that specialised interventional treatment can be delivered in tertiary care centres across our national network. This may pave the way for an improved, standardised approach to the treatment of pulmonary embolism, reducing the acute risks that patients face.
Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism
New England Journal of Medicine · Kroupa et al. ·
AHA Scientific Sessions 2026 · Lp(a)HORIZON
Written before results
Raul D. Santos
General / Preventive / Lipids
We'll have important results to discuss soon!
Pregnancy Outcomes After Living Kidney Donation
JAMA · Carol Wang et al. ·
Jörg Hausleiter
“
Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention.
Tricuspid-Valve Intervention in Heart Failure
New England Journal of Medicine · Hausleiter et al. ·
Dr. Sophia Zoungas
Lead Researcher · Monash University School of Public Health and Preventive Medicine
“
A notable finding is that the lower incidence of major, nonfatal cardiovascular events with atorvastatin than with placebo did not result in a corresponding improvement in disability-frees survival. Explanations for this result might include the fact that 80% of the deaths in the trial were from non-cardiovascular causes.
Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults
New England Journal of Medicine · Zoungas et al. ·
Boyoung Joung
“
The key impact on clinical practice is that the level of evidence about this population was actually very low, and this is the first [randomized controlled trial] to support that DOAC therapy can give benefit to this patient population.
Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk
New England Journal of Medicine · Kim et al. ·
Dr. Henning Bundgaard
Cardiologist · Copenhagen University Hospital
“
It seems that from POET I and POET II we have challenged dogmas showing that less intensive antibiotic therapy after stabilization is superior and safe. And we think that defining the stabilization point is a kind of personalizing endocarditis treatment.
Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis
New England Journal of Medicine · Bundgaard et al. ·
Dr. Matthew J. Reed
Professor of Emergency Medicine · The Usher Institute, University of Edinburgh
“
Although immediate ECG monitoring did not reduce recurrent fainting, it enabled earlier identification of serious cardiac rhythm disorders, allowing patients to receive treatment much sooner, reducing uncertainty and anxiety, and potentially preventing avoidable deaths.
Immediate Ambulatory Electrocardiographic Monitoring in Syncope
New England Journal of Medicine · Reed et al. ·
Dr. Ahmad Masri
Cardiologist · Oregon Health & Science University
“
Results from the ACACIA-HCM trial provide really positive news for patients with symptomatic non-obstructive HCM. For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease.
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
New England Journal of Medicine · Masri et al. ·
Giuseppe Biondi-Zoccai
Expert commentary · @gbiondizoccai
“
In the 986-patient TAVI PCI RCT, a strategy of TAVI before PCI yielded similar outcome to a strategy of PCI before TAVI at 1 year in patients with both aortic stenosis and CAD (25% MVD) https://t.co/8d0elI9CeM #CAD #PCI #TAVI #TAVR @NEJM @escardio https://t.co/OEZFeSNXLq
Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation
New England Journal of Medicine · Stähli et al. ·
Dr. Hang Zhang
Cardiologist · Nanjing First Hospital
“
Despite major advances in pharmacologic and device-based therapies, pulmonary hypertension remains one of the strongest predictors of hospitalization, right ventricular failure, and death in patients with left heart disease and heart failure. … Additional long-term follow-up will be important to determine whether the observed mid-term improvements translate into sustained reductions in mortality and hospitalization for HF.
Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension
New England Journal of Medicine · Zhang et al. ·
Nick Mills
BHF Professor of Cardiology, University of Edinburgh · University of Edinburgh
“
Our findings provide strong evidence that patients who have had a heart attack excluded do not benefit from early outpatient CTCA scans. Once we are confident that they haven't had a heart attack, we can reassure these patients that their future risk is low and send them home.
Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain
